<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143068">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02092584</url>
  </required_header>
  <id_info>
    <org_study_id>5144</org_study_id>
    <nct_id>NCT02092584</nct_id>
  </id_info>
  <brief_title>Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD.</brief_title>
  <official_title>Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With Cardiovascular Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the comparison between the effects of supplementation with omega 3
      or placebo for 8 weeks in serum level of IGF-1 and IGFBP-3 and gene expression of IGF-1 in
      patients with cardiovascular disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Serum Total Cholesterol</measure>
    <time_frame>Change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum HDL-C</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum LDL-C</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum TG</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Fasting Blood Sugar(FBS)</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Insulin</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum hsCRP</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Insulin Like Growth Factor-1(IGF-1)</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum IGF binding protein 3(IGFBP-3)</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gene Expression of IGF-1</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression of IGFBP3</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>CVD, Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with Cardiovascular disease who receive 4g/d omega-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVD, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with cardiovascular disease who receive 4 cap of placebo/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>4 cap 1 g Omega-3 per day for 2 months</description>
    <arm_group_label>CVD, Omega-3</arm_group_label>
    <other_name>n-3 fatty acids</other_name>
    <other_name>n-3 PUFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 cap 1 g Placebo(paraffin) per day for 2 months</description>
    <arm_group_label>CVD, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CVD patients 45- 65 years old, patients with â‰¥ 50% stenosis in at least one coronary
             angiogram demonstrated, body mass index in the range 18.5- 35, avoidance of dietary
             supplements, vitamins and herbal products at least 3 months before and throughout the
             intervention, willingness to participation,

        Exclusion Criteria:

          -  people who have used omega 3 supplements in last 3 months, having chronic renal
             disease , GI disease, hepatobiliary diseases, hematological disorders, hypo- or
             hyperthyroidism, Smokers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atherosclerotic</keyword>
  <keyword>IGF-1</keyword>
  <keyword>IGFBP-3</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
